176 related articles for article (PubMed ID: 38200153)
1. PRKCSH contributes to TNFSF resistance by extending IGF1R half-life and activation in lung cancer.
Shin GC; Lee HM; Kim N; Seo SU; Kim KP; Kim KH
Exp Mol Med; 2024 Feb; 56(1):192-209. PubMed ID: 38200153
[TBL] [Abstract][Full Text] [Related]
2. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.
Manabe T; Yasuda H; Terai H; Kagiwada H; Hamamoto J; Ebisudani T; Kobayashi K; Masuzawa K; Ikemura S; Kawada I; Hayashi Y; Fukui K; Horimoto K; Fukunaga K; Soejima K
Mol Cancer Res; 2020 Apr; 18(4):549-559. PubMed ID: 31941753
[No Abstract] [Full Text] [Related]
3. Potential role of PRKCSH in lung cancer: bioinformatics analysis and a case study of Nano ZnO.
Lei R; Zhou M; Zhang S; Luo J; Qu C; Wang Y; Guo P; Huang R
Nanoscale; 2022 Mar; 14(12):4495-4510. PubMed ID: 35254362
[TBL] [Abstract][Full Text] [Related]
4. PRKCSH contributes to tumorigenesis by selective boosting of IRE1 signaling pathway.
Shin GC; Moon SU; Kang HS; Choi HS; Han HD; Kim KH
Nat Commun; 2019 Jul; 10(1):3185. PubMed ID: 31320625
[TBL] [Abstract][Full Text] [Related]
5. PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer.
Wang Q; Wang X; Li J; Yin T; Wang Y; Cheng L
Sci Rep; 2024 Jan; 14(1):1778. PubMed ID: 38245572
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
[TBL] [Abstract][Full Text] [Related]
7. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
[TBL] [Abstract][Full Text] [Related]
8. Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.
Day TF; Kallakury BVS; Ross JS; Voronel O; Vaidya S; Sheehan CE; Kasid UN
Mol Cancer Res; 2019 May; 17(5):1207-1219. PubMed ID: 30647104
[TBL] [Abstract][Full Text] [Related]
9. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
[TBL] [Abstract][Full Text] [Related]
10. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors.
Evdokimova V; Tognon CE; Benatar T; Yang W; Krutikov K; Pollak M; Sorensen PH; Seth A
Sci Signal; 2012 Dec; 5(255):ra92. PubMed ID: 23250396
[TBL] [Abstract][Full Text] [Related]
11. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
[TBL] [Abstract][Full Text] [Related]
12. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A; Jebaraj BMC; Tausch E; Bloehdorn J; Ghia P; Yahiaoui A; Dolnik A; Blätte TJ; Bullinger L; Dheenadayalan RP; Li L; Schneider C; Chen SS; Chiorazzi N; Dietrich S; Seiffert M; Tannheimer S; Döhner H; Mertens D; Stilgenbauer S
Blood; 2019 Aug; 134(6):534-547. PubMed ID: 31010847
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun SY; He Y; Zhou W
Lung Cancer; 2018 Sep; 123():36-43. PubMed ID: 30089593
[TBL] [Abstract][Full Text] [Related]
14. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
15. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
16. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
17. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
18. IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression.
Alfaro-Arnedo E; López IP; Piñeiro-Hermida S; Canalejo M; Gotera C; Sola JJ; Roncero A; Peces-Barba G; Ruíz-Martínez C; Pichel JG
Oncogene; 2022 Jul; 41(28):3625-3639. PubMed ID: 35688943
[TBL] [Abstract][Full Text] [Related]
19. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
20. Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Isoyama S; Kajiwara G; Tamaki N; Okamura M; Yoshimi H; Nakamura N; Kawamura K; Nishimura Y; Namatame N; Yamori T; Dan S
Cancer Sci; 2015 Feb; 106(2):171-8. PubMed ID: 25483727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
